Skip to content

Nonlinear Absorber in Essential Tremor Treatment

Nonlinear Absorber in Essential Tremor Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06397391
Acronym
TREM-AB
Enrollment
5
Registered
2024-05-02
Start date
2024-08-30
Completion date
2025-04-04
Last updated
2025-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Tremor

Keywords

Essential tremor, Passive treatment, Nonlinear absorber

Brief summary

The goal of this study is to develop a non linear absorber for patients with essential tremor (ET). It 's an extern passive medical device which should improve patients tremor. Investigators will evaluate the impact of this medical device through one clinical scale (Fahn-Tolosa-Marin) and accelerometry record. Investigators focus on motor improvement.

Interventions

DEVICETREM-AB

Wearing medical device on site during 1 hour

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Adult man or woman between 20 and 90 years old * Diagnosis of ET (Essential Tremor) established by a neurologist * ET affecting the upper limbs, associated or not with head tremor * Drug-resistant nature of ET (failure of beta-blockers, mysoline, benzodiazepine) * Affiliate to a social security or similar system * Having given written consent to participate in the study, free and informed.

Exclusion criteria

* Severe comorbidity * ET affecting only the leader * Wounds on the forearm * Modification of treatment or surgery to manage ET, planned within 3 months following inclusion * Cognitive disorder known or suspected by the investigator * Pregnant or breastfeeding woman * Persons placed under guardianship, curatorship or under judicial protection * Persons deprived of liberty, subject to psychiatric care or admitted to a health or social establishment for purposes other than that of clinical investigation Criteria for premature discharge * MMSE (Mini-Mental State Examination) score\<24; * ET of the patient with frequency range not between 4 to 6 Hz or 8 to 12 Hz and/or amplitudes of movement greater than 20°. * modification of treatment for ET or performance of tremor surgery before the final visit; * withdrawal of consent or refusal to continue visits.

Design outcomes

Primary

MeasureTime frameDescription
Tremor improvement6 months maximumTo assess tremor improvement, investigators will use the Fahn-Tolosa-Marin rating scale. This scale allows, thanks to a score, to assess clinical and functional evaluation of the tremor. Different aspect of the tremor are evaluate like the frequency of the tremor of the head, hand, arm..etc. and the impact of the tremor on daily actions (like writing, drawing, …). This score will be assessed at Visit 1 and 2. During visit 2, the assessment will be performed before and 1 hour after wearing the device.

Secondary

MeasureTime frameDescription
Tremor frequency6 months maximumTo assess tremor frequency, investigators will use accelerometry record and electromyography. This score will be assessed at Visit 1 and 2. During visit 2, the assessment will be performed before and 1 hour after wearing.the device.
Tolerance to wearing the device6 months maximumAdverse reactions occurring during use of the device
Patient satisfaction with the device measured by a specific multidimensional questionnaire6 months maximumA multidimensional questionnaire has been built specifically for the study. An EVA scale is used to assess whether the patient has experienced discomfort, pain or discomfort (0-10). The higher the score, the more severe the discomfort. Ease of installation of the device and intention to use it on a daily basis if this was possible are evaluated by questions with binary responses (yes or no). Free fields are used to complete these responses and to suggest improvements of the prototype. This score will be assessed at the end of Visit 2

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026